The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease

Antioxidants and Redox Signaling

Volumn 17, Issue 6, 2012, Pages 860-877

  Kupershmidt, Lana ^a   Amit, Tamar ^a   Bar Am, Orit ^a   Youdim, Moussa B H ^a   Weinreb, Orly ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; IRON; IRON CHELATING AGENT; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; PRESENILIN 1; PROTEIN KINASE B; PROTEIN KINASE C; TAU PROTEIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; DRUG EFFECT; FEEDING BEHAVIOR; FRONTAL CORTEX; HIPPOCAMPUS; LEARNING; MALE; MEMORY CONSOLIDATION; MOUSE; NESTING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARIETAL CORTEX; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR AMYLOIDOSIS; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; HYDROXYQUINOLINES; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PRESENILIN-1; REAL-TIME POLYMERASE CHAIN REACTION;

MUS;

EID: 84863896457     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4279     Document Type: Article

References (65)

1. Avramovich-Tirosh Y, Amit T, Bar-Am O, Weinreb O, and Youdim MB. Physiological and pathological aspects of Abeta in iron homeostasis via 5¢UTR in the APP mRNA and the therapeutic use of iron-chelators. BMC Neurosci 9: S2, 2008.
2. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, and Youdim MB. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelatormonoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 100: 490-502, 2007.
3. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, and Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res, 7: 300-306, 2010.
4. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, and Youdim MB. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4: 403-411, 2007.
5. Bandyopadhyay S, Goldstein LE, Lahiri DK, and Rogers JT. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 14: 2848-2864, 2007.
6. Bar-Am O, Amit T, Weinreb O, Youdim MB, and Mandel S. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 21: 361-371, 2010.
7. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214, 2003.
8. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, and Rogers JT. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 285: 31217-3123, 2010.
9. Deacon RM, Cholerton LL, Talbot K, Nair-Roberts RG, Sanderson DJ, Romberg C, Koros E, Bornemann KD, and Rawlins JN. Age-dependent and-independent behavioral deficits in Tg2576 mice. Behav Brain Res 189: 126-138, 2008.
10. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, Allsbrook M, McDonald MP, and Fan GH. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 28: 11622-11634, 2008.
11. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, and Carey PR. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry, 42: 2268-2273, 2003.
12. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, and Bush AI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142: 857-867, 2010.
13. El Tannir El Tayara N, Delatour B, Le Cudennec C, Guegan M, Volk A, and Dhenain M. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 22: 199-208, 2006.
14. Engel T, Hernandez F, Avila J, and Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26: 5083-5090, 2006.
15. Falangola MF, Lee SP, Nixon RA, Duff K, and Helpern JA. Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res 30: 201-205, 2005.
16. Filali M, Lalonde R, and Rivest S. Cognitive and noncognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 8: 143-148, 2009.
17. Fumagalli F, Racagni G, and Riva MA. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 6: 95-104, 2006.
18. Gal S, Zheng H, Fridkin M, and Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95: 79-88, 2005.
19. Gengler S, Hamilton A, and Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One 5: e9764, 2010.
20. Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, and Heldman E. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem 71: 2094-2103, 1998.
21. Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L, and Zatta P. Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 17: 457-468, 2009.
22. Hernandez F, Borrell J, Guaza C, Avila J, and Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83: 1529-1533, 2002.
23. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102, 1996.
24. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, and Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13: 159-170, 2004.
25. Kalaria RN, Sromek SM, Grahovac I, and Harik SI. Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease. Brain Res 585: 87-93, 1992.
26. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736, 1987.
27. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, and Weinreb O. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 2012; DOI.org/10.1016/j.mad.2012.03.001.
28. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, and Youdim MB. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 189: 345-358, 2011.
29. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, and Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motorneuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23: 3766-3779, 2009.
30. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, AhlijanianMK, and Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163: 83-95, 2003.
31. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, Hider R, Marciniak SJ, Lomas DA, and Crowther DC. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 286: 4248-4256, 2011.
32. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52, 1998.
33. Lovestone S and Reynolds CH. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324, 1997.
34. Lukacs H, Hiatt ES, Lei ZM, and Rao CV. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. Horm Behav 29: 42-58, 1995.
35. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, and Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28: 6333-6341, 2008.
36. Mandel S, Amit T, Bar-Am O, and Youdim MB. Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 82: 348-360, 2007.
37. Masuda T, Kasai T, and Satodate R. Quantitative measurement of hemosiderin deposition in tissue sections of the liver by image analysis. Anal Quant Cytol Histol 15: 379-382, 1993.
38. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, and Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 279: 751-755, 2000.
39. Moolman DL, Vitolo OV, Vonsattel JP, and Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 33: 377-387, 2004.
40. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47-60, 1984.
41. Murer MG, Yan Q, and Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71-124, 2001.
42. Naoi M and Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 9: 1233-1250, 2009.
43. Nguyen-Legros J, Bizot J, Bolesse M, and Pulicani JP. ["Diaminobenzidine black" as a new histochemical demonstration of exogenous iron (author's transl)]. Histochemistry 66: 239-244, 1980.
44. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: An update. Ann NY Acad Sci 1012: 1-13, 2004.
45. Rabinovitch MS and Rosvold HE. A closed-field intelligence test for rats. Can J Psychol 5: 122-128, 1951.
46. Reiserer RS, Harrison FE, Syverud DC, and McDonald MP. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 6: 54-65, 2007.
47. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, and Gullans SR. An iron-responsive element type II in the 5¢-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528, 2002.
48. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, and Buee L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169: 599-616, 2006.
49. Schonberg DL and McTigue DM. Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation. Exp Neurol 218: 64-74, 2009.
50. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
51. Shemyakov SE. Monoamine oxidase activity, lipid peroxidation, and morphological changes in human hypothalamus during aging. Bull Exp Biol Med 131: 586-588, 2001.
52. Siegel GJ and Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 33: 199-227, 2000.
53. Stanford L and Brown RE. MHC-congenic mice (C57BL/6J and B6-H-2K) show differences in speed but not accuracy in learning the Hebb-Williams Maze. Behav Brain Res 144: 187-197, 2003.
54. Traissard N, Herbeaux K, Cosquer B, Jeltsch H, Ferry B, Galani R, Pernon A, Majchrzak M, and Cassel JC. Combined damage to entorhinal cortex and cholinergic basal forebrain neurons, two early neurodegenerative features accompanying Alzheimer's disease: Effects on locomotor activity and memory functions in rats. Neuropsychopharmacology 32: 851-871, 2007.
55. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, and Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55: 801-814, 2004.
56. Weinreb O, Amit T, Bar-Am O, and Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: New insights and implications for therapy. Ann NY Acad Sci 1122: 155-168, 2007.
57. Weinreb O, Amit T, Mandel SA, Kupershmidt L, and Youdim MB. Neuroprotective multifunctional iron chelators: From redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 13: 919-949, 2010.
58. Weinreb O, Mandel S, Bar-Am O, and Amit T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: A tribute to Moussa Youdim. J Neural Transm 118: 479-492, 2011.
59. Yamada K, Noda Y, Hasegawa T, Komori Y, Nikai T, Sugihara H, and Nabeshima T. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther 276: 460-466, 1996.
60. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-6891, 1996.
61. Zhang H, Ma Q, Zhang YW, and Xu H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 12: 9-2, 2012.
62. Zhang HY. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett 579: 5260-5264, 2005.
63. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, and Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95: 68-78, 2005.
64. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, and Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13: 773-783, 2005.
65. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, and Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844, 2007.